Medincell SA
MEDCL.PA- Latest Trade
- trading higher8.05EUR
- 0.38
- 4.95%
- As of Jan 28 2023. Values delayed up to 15 minutes
- Day Range
- 7.67 - 8.08
- 52-Week Range
- 4.73 - 9.09
- Previous Close
- 7.67
- Open
- 7.67
- Volume
- 37,650.00
- 3 Month Average Trading Volume
- 0.61
- Shares Out (Mil)
- 25.11
- Market Cap
- 202.47
- Forward P/E
- -20.92
- Dividend Yield
- 0.00
Key Statistics
1.75 mean rating - 4 analysts
- P/E Excl. Extra Items (TTM)
- 0.00
- Price To Sales (TTM)
- 23.78
- Price To Book (Quarterly)
- 0.00
- Price To Cash Flow (Per Share TTM)
- 0.00
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -97.55
- Return On Equity (TTM)
- -61.19
2021 (millions USD)
About Medincell SA (MEDCL.PA)
Company Information
Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The Company is focused on the development of therapeutic solutions with worldwide access. The Company works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
Address
3 rue des Freres LumiereJACOU,
34830
France
Industry
Biotechnology & Drugs
Executive Leadership
- Anh Nguyen
- Chairman of the Supervisory Board
- Christophe Douat
- Chairman of the Management Board
- Sabri Markabi
- Independent Vice Chairman of the Supervisory
- Jaime Arango
- Chief Financial Officer, Member of the Management Board
- Franck Pouzache
- Human Resources Director, Member of the Management Board
- Richard Malamut
- Chief Medical Officer, Member of the Management Board
- Joel Richard
- Director - Technical and Pharmaceutical Operations, Member of the Management Board
- Philippe Guy
- Independent Member of the Supervisory Board
- Elisabeth Kogan
- Independent Member of the Supervisory Board
- Virginie Lleu
- Independent Member of the Supervisory Board
- Karine Lignel
- Member of the Supervisory Board - Permanent Representative of Credit Mutuel Innovation
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,927.60 | 0.12% |
| Copper | 783.30 | 1.20% |
| Brent Crude Oil | 86.66 | -- |
| CBOT Soybeans | 1,512.25 | 0.74% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,070.56 | 0.25% |
| Euro STOXX 50 | 4,178.01 | 0.10% |
| FTSE 100 | 7,765.15 | 0.05% |
| Nikkei 225 | 27,382.56 | 0.07% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes